The A-List: 2009's Trend-Shaping Series A Financings
This article was originally published in Start Up
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
You may also be interested in...
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
Initial public offerings by life sciences companies spanned the alphabet over the past two weeks, but each of three IPOs had one common factor - significant discounts in opening share prices.